The role of IL-28, IFN-?, and TNF-? in predicting response to pegylated interferon/ribavirin in chronic HCV patients

Simple item page
dc.AffiliationOctober University for modern sciences and Arts (MSA)
dc.contributor.authorAbdou A.G.
dc.contributor.authorAsaad N.Y.
dc.contributor.authorEhsan N.
dc.contributor.authorEltahmody M.
dc.contributor.authorEl-Sabaawy M.M.
dc.contributor.authorElkholy S.
dc.contributor.authorElnaidany N.F.
dc.contributor.otherDepartment of Pathology
dc.contributor.otherFaculty of Medicine
dc.contributor.otherMenofiya University
dc.contributor.otherShebein Elkom
dc.contributor.otherEgypt; Department of Pathology
dc.contributor.otherLiver Institute
dc.contributor.otherMenofiya University
dc.contributor.otherShebein Elkom
dc.contributor.otherEgypt; Hepatology Department
dc.contributor.otherLiver Institute
dc.contributor.otherMenofiya University
dc.contributor.otherShebein Elkom
dc.contributor.otherEgypt; Clinical Pharmacy Department
dc.contributor.otherMSA October University
dc.contributor.otherShebein Elkom
dc.contributor.otherEgypt
dc.date.accessioned2020-01-09T20:41:57Z
dc.date.available2020-01-09T20:41:57Z
dc.date.issued2015
dc.descriptionScopus
dc.description.abstractThe primary goal of HCV therapy is to achieve a sustained virological response (SVR). Many host and viral factors influence the treatment response. Cytokines play an important role in the defense against viral infections, where successful treatment of hepatitis C depends on a complex balance between pro- and anti-inflammatory responses. In the present study, we investigated the relationship between the presence and percentage of some cytokines (IL-28, IFN-?, and TNF-?) regarding different clinicopathological parameters including response to therapy in chronic HCV patients using immunohistochemical technique. This study was carried out on 64 chronic HCV patients (34 responders and 30 non-responders). Of cases, 54% showed IL-28 expression, which was associated with low AST (p�=�0.002) and low HAI score (p�=�0.006). Of cases, 67 and 45% showed IFN-? and TNF-? expression, respectively, where the median percentage of TNF-? expression was higher in grade II spotty necrosis compared to grade I. Some inflammatory cytokines expressed by intrahepatic inflammatory cells in chronic HCV patients promote inflammation and injury (pro-inflammatory) such as TNF-?. Other cytokines aid in resolving inflammation and injury (anti-inflammatory) such as IL-28. The balance between these cytokines will determine the degree of inflammatory state. None of the investigated cytokines proved its clear cut role in affecting response to therapy, however, their levels varied between responders and non-responders for further investigations to clarify. � 2014 APMIS. Published by John Wiley & Sons Ltd.en_US
dc.description.urihttps://www.scimagojr.com/journalsearch.php?q=12425&tip=sid&clean=0
dc.identifier.doihttps://doi.org/10.1111/apm.12301
dc.identifier.doiPubMed ID 25131720
dc.identifier.issn9034641
dc.identifier.otherhttps://doi.org/10.1111/apm.12301
dc.identifier.otherPubMed ID 25131720
dc.identifier.urihttps://t.ly/J3wrl
dc.language.isoEnglishen_US
dc.publisherBlackwell Munksgaarden_US
dc.relation.ispartofseriesAPMIS
dc.relation.ispartofseries123
dc.subjectOctober University for Modern Sciences and Arts
dc.subjectUniversity for Modern Sciences and Arts
dc.subjectMSA University
dc.subjectجامعة أكتوبر للعلوم الحديثة والآداب
dc.subjectChronic HCVen_US
dc.subjectIFN?en_US
dc.subjectIL-28en_US
dc.subjectImmunohistochemistryen_US
dc.subjectPegylated interferon/ribavirinen_US
dc.subjectResponse to therapyen_US
dc.subjectTNF-?en_US
dc.subjectalanine aminotransferaseen_US
dc.subjectalpha fetoproteinen_US
dc.subjectaspartate aminotransferaseen_US
dc.subjectgamma interferonen_US
dc.subjectinterleukin 28en_US
dc.subjectpeginterferon alpha2aen_US
dc.subjectribavirinen_US
dc.subjecttumor necrosis factor alphaen_US
dc.subjectvirus RNAen_US
dc.subjectalanine aminotransferaseen_US
dc.subjectalpha interferonen_US
dc.subjectaspartate aminotransferaseen_US
dc.subjectbiological markeren_US
dc.subjectgamma interferonen_US
dc.subjectIL28A protein, humanen_US
dc.subjectinterleukin derivativeen_US
dc.subjectmacrogol derivativeen_US
dc.subjectpeginterferon alpha2aen_US
dc.subjectrecombinant proteinen_US
dc.subjectribavirinen_US
dc.subjecttumor necrosis factor alphaen_US
dc.subjectadulten_US
dc.subjectalanine aminotransferase blood levelen_US
dc.subjectArticleen_US
dc.subjectaspartate aminotransferase blood levelen_US
dc.subjectcontrolled studyen_US
dc.subjectdisease associationen_US
dc.subjectdisease severityen_US
dc.subjectfemaleen_US
dc.subjecthepatitis Cen_US
dc.subjecthumanen_US
dc.subjecthuman cellen_US
dc.subjecthuman tissueen_US
dc.subjectimmunohistochemistryen_US
dc.subjectinflammatory cellen_US
dc.subjectlymphocyteen_US
dc.subjectmajor clinical studyen_US
dc.subjectmaleen_US
dc.subjectoutcome assessmenten_US
dc.subjectportal veinen_US
dc.subjectpriority journalen_US
dc.subjectprotein expressionen_US
dc.subjectretrospective studyen_US
dc.subjecttreatment responseen_US
dc.subjectblooden_US
dc.subjectdrug combinationen_US
dc.subjectHepacivirusen_US
dc.subjectHepatitis C, Chronicen_US
dc.subjectimmunologyen_US
dc.subjectmiddle ageden_US
dc.subjectnonparametric testen_US
dc.subjectvirologyen_US
dc.subjectyoung adulten_US
dc.subjectAdulten_US
dc.subjectAlanine Transaminaseen_US
dc.subjectAspartate Aminotransferasesen_US
dc.subjectBiological Markersen_US
dc.subjectDrug Therapy, Combinationen_US
dc.subjectFemaleen_US
dc.subjectHepacivirusen_US
dc.subjectHepatitis C, Chronicen_US
dc.subjectHumansen_US
dc.subjectImmunohistochemistryen_US
dc.subjectInterferon-alphaen_US
dc.subjectInterferon-gammaen_US
dc.subjectInterleukinsen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectPolyethylene Glycolsen_US
dc.subjectRecombinant Proteinsen_US
dc.subjectRetrospective Studiesen_US
dc.subjectRibavirinen_US
dc.subjectStatistics, Nonparametricen_US
dc.subjectTumor Necrosis Factor-alphaen_US
dc.subjectYoung Adulten_US
dc.titleThe role of IL-28, IFN-?, and TNF-? in predicting response to pegylated interferon/ribavirin in chronic HCV patientsen_US
dc.typeArticleen_US
dcterms.isReferencedByZhang, L., Gwinn, M., Hu, D.J., Viral hepatitis C gets personal - the value of human genomics to public health (2013) Public Health Genomics, 16, pp. 192-197; McHutchison, J.G., Lawitz, E.J., Shiffman, M.L., Muir, A.J., Galler, G.W., McCone, J., Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection (2009) N Engl J Med, 361, pp. 580-593; Wui, L., Wang, H., Geng, X., Two IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C in different racial populations: a meta-analysis (2012) Exp Ther Med, 3, pp. 200-206; Shirakawa, H., Matsumoto, A., Joshita, S., Komatsu, M., Tanaka, N., Umemura, T., Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors (2008) Hepatology, 48, pp. 1753-1760; Kamal, S.M., Fehr, J., Roesler, B., Peters, T., Rasenack, J.W., Peginterferon alone or in combination with ribavirin enhances HCV specific CD4+ T helper 1 responses in patients with chronic hepatitis C (2002) Gastroenterology, 123, pp. 1070-1083; Mogensen, T.H., Pathogen recognition and inflammatory signaling in innate immune defenses (2009) Clin Microbiol Rev, 22, pp. 240-273; Clark, V., Nelson, D.R., The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C (2012) Liver Int, 32, pp. 103-107; Atsukawa, M., Nakatsuka, K., Kobayashi, T., Shimizu, M., Tamura, H., Harimoto, H., Ribavirin downmodulates inducible costimulator on CD4+ T cells and their interleukin-10 secretion to assist in hepatitis C virus clearance (2012) J Gastroenterol Hepatol, 27, pp. 823-831; Yoneda, S., Umemura, T., Katsuyama, Y., Kamijo, A., Joshita, S., Komatsu, M., Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients (2011) J Infect Dis, 203, pp. 1087-1095; Umemura, T., Joshita, S., Yoneda, S., Katsuyama, Y., Ichijo, T., Matsumoto, A., Serum interleukin (IL)-10 and IL-12 levels and IL28B gene polymorphisms: pretreatment prediction of treatment failure in chronic hepatitis C (2011) Antivir ther, 16, pp. 1073-1080; Cacciarelli, T.V., Martinez, O.M., Gish, R.G., Gish, R.G., Villanueva, J.C., Krams, S.M., Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and post-treatment with interferon alfa (1996) Hepatology, 24, pp. 6-9; Tsai, S.L., Sheen, I.S., Chien, R.N., Chu, C.M., Huang, H.C., Chuang, Y.L., Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications (2003) J Biomed Sci, 10, pp. 120-135; Wan, L., Kung, Y.J., Lin, Y.J., Liao, C.C., Sheu, J.J., Tsai, Y., Th1 and Th2 cytokines are elevated in HCV-infected SVR(-) patients treated with interferon-alpha (2009) Biochem Biophys Res Commun, 379, pp. 855-860; Ishak, K., Baptista, A., Bianchi, L., Callea, F., De Groote, J., Gudat, F., Histologic grading and staging of chronic hepatitis (1995) J Hepatol, 24, pp. 289-293; Theise, N.D., Bodenheimer, H.C., Jr., Ferrell, L.D., Acute and chronic viral hepatitis (2007) MacSween's Pathology of the Liver, pp. 399-442. , Burt AD, Portmann BC, Ferrell LD, editors., 5th Edition, Chapter 8. Philadelphia, USA: Elsevier; Bedossa, P., Poynard, Y., An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group (1996) Hepatology, 24, pp. 289-293; Brunt, E.M., Janney, C.G., Di Bisceglie, A.M., Neuschwander-Tetri, B.A., Bacon, B.R., Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions (1999) Am J Gastroenterol, 94, pp. 2467-2474; Ag�ndez, J.A., Garc�a-Martin, E., Maestro, M.L., Cuenca, F., Mart�nez, C., Ortega, L., Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease (2012) PLoS ONE, 7, p. e37998; Langhans, B., Kupfer, B., Braunschweiger, I., Arndt, S., Schulte, W., Nischalke, H.D., Interferon-lambda serum levels in hepatitis C (2011) J Hepatol, 54, pp. 859-865; Ge, D., Fellay, J., Thompson, A.J., Simon, J.S., Shianna, K.V., Urban, T.J., Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance (2009) Nature, 461, pp. 399-401; Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M.L., IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy (2009) Nat Genet, 41, pp. 1100-1104; Thomas, D.L., Thio, C.L., Martin, M.P., Qi, Y., Ge, D., O'Huigin, C., Genetic variation in IL28B and spontaneous clearance of hepatitis C virus (2009) Nature, 461, pp. 798-801; Rauch, A., Kutalik, Z., Descombes, P., Cai, T., Di Iulio, J., Mueller, T., Genetic variation in IL28B is associated with chronic hepatitis C andtreatment failure: a genome-wide association study (2010) Gastroenterology, 138, pp. 1338-1345; Abe, H., Ochi, H., Maekawa, T., Hayes, C.N., Tsuge, M., Miki, D., Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients (2010) J Hepatol, 53, pp. 439-443; Thompson, A.J., Clark, P.J., Zhu, M., Zhu, Q., Ge, D., Sulkowski, M.S., Genome wide-association study identifies IL28B polymorphism to be associated with baseline ALT and hepatic necro-inflammatory activity in chronic hepatitis C patients enrolled in the IDEAL study (2010) Hepatology, 52, pp. 1220A-1221A; Larrea, E., Garcia, N., Qian, C., Civeira, M.P., Prieto, J., Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C (1996) Hepatology, 23, pp. 210-217; Zhu, N., Khoshnan, A., Schneider, R., Matsumoto, M., Dennert, G., Ware, C., Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis (1998) J Virol, 72, pp. 3691-3697; Knobler, H., Zhornicky, T., Sandler, A., Haran, N., Ashur, Y., Schattner, A., Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association (2003) Am J Gastroenterol, 98, pp. 2751-2756; Schoenborn, J.R., Wilson, C.B., Regulation of interferon-gamma during innate and adaptive immune responses (2007) Adv Immunol, 96, pp. 41-101; Par, G., Szereday, L., Berki, T., Palinkas, L., Halasz, M., Miseta, A., Increased baseline proinflammatory cytokine production in chronic hepatitis C patients with rapid virological response to peginterferon plus ribavirin (2013) PLoS ONE, 8, p. e67770; Dumoulin, F.L., Wennrich, U., Nischalke, H.D., Leifeld, L., Fischer, H.P., Sauerbruch, T., Intrahepatic mRNA levels of interferon gamma and tumor necrosis factor alpha and response to antiviral treatment of chronic hepatitis C (2001) J Hum Virol, 4, pp. 195-199; Lio, D., Caruso, C., Di Stefano, R., Colonna Romano, G., Ferraro, D., Scola, L., IL-10 and TNF-? polymorphisms and the recovery from HCV infection (2003) Hum Immunol, 64, pp. 674-680; Bumgardner, G.L., Li, J., Apte, S., Heininger, M., Frankel, W.L., Effect of tumor necrosis factor alpha and intercellular adhesion molecule-1 expression on immunogenicity of murine liver cells in mice (1998) Hepatology, 28, pp. 466-474; Park, J., Kang, W., Ryu, S.W., Kim, W.I., Chang, D.Y., Lee, D.H., Hepatitis C virus infection enhances TNF-alpha induced cell death via suppression of NF-kB (2012) Hepatology, 56, pp. 831-840; Zylberberg, H., Rimaniol, A.C., Pol, S., Masson, A., De Groote, D., Berthelot, P., Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity (1999) J Hepatol, 30, pp. 185-191; Itoh, Y., Okanoue, T., Ohnishi, N., Sakamoto, M., Nishioji, K., Nakagawa, Y., Serum levels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis C virus infection (1999) Am J Gastroenterol, 94, pp. 1332-1340; Ren, Y., Duan, Z.H., Meng, Q.H., Li, Z., Li, J., [Relationship between the level of serum TNF-alpha of patients with chronic hepatitis C and treatment with interferon-alpha and the influencing factors] (2009) Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, 23, pp. 129-131; Kotenko, S.V., Gallagher, G., Baurin, V.V., Lewis-Antes, A., Shen, M., Shah, N.K., IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex (2003) Nat Immunol, 4, pp. 69-77; Sheppard, P., Kindsvogel, W., Xu, W., Henderson, K., Schlutsmeyer, S., Whitmore, T.E., IL-28, IL-29 and their class II cytokine receptor IL-28R (2003) Nat Immunol, 4, pp. 63-68
dcterms.sourceScopus

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
avatar_scholar_256.png
Size:
6.31 KB
Format:
Portable Network Graphics
Description:
Download

Collections

Faculty Of Pharmacy Research Paper